Infrared Photobiomodulation in Humans With Epilepsy

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Beth Israel Deaconess Medical Center
Study ID
NCT07145489
Status
Recruiting
Apply to this trial

Conditions

  • Drug Resistant Epilepsy

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • photobiomodulation — DEVICE
    a hat with infrared lights will be worn for 30 minutes daily for 6 months

Study Details

Drug-resistant epilepsy represents roughly 40% of people with epilepsy. It is very challenging to stop seizures in this condition, and the treatment options are limited. This study aims to investigate a new treatment that involves using infra-red light. In animals, this treatment has shown promise as a possible way to reduce seizures, but it has not been tested in humans for this. The investigators are interested to know if it can reduce seizures, and how comfortable it is to be treated with this therapy.

Key Dates

Start date
Nov 25, 2025
Status verified
Feb 2026
Primary completion
Sep 25, 2026
Completion
Sep 25, 2027

Study Design

Enrollment
13 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: photobiomodulation
    participants will use photobiomodulation daily for 6 months

Primary Outcome Measure

seizure rate reduction [ Time Frame: 6 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
BIDMCBostonMassachusetts02215
Daniel Goldenholz, MD PhD
[email protected]
617-632-8930
Daniel Goldenholz, MD PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Boston, MA

By research site
BIDMC· Boston, MA

Related Studies